StockData
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc (MREO) stock

MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 1/30
$0.28−0.01 (-4.94%)

Close on Nov 19, 2026Market cap $43.92MP/E –Yield –

Mereo BioPharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Mereo BioPharma's operating income for the twelve months ending Sep 30, 2026 was -$30.40M. For fiscal 2025 it was -$40.11M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$40.11M–
FY2024Dec 31, 2024-$47.36M–
FY2023Dec 31, 2023-$28.42M–
FY2022Dec 31, 2022-$54.43M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$6.22M–
Q2 FY2026Jun 30, 2026-$7.03M–
Q1 FY2026Mar 31, 2026-$8.77M–
Q4 FY2025Dec 31, 2025-$8.39M–
Q3 FY2025Sep 30, 2025-$10.02M–
Q2 FY2025Jun 30, 2025-$10.50M–
Q1 FY2025Mar 31, 2025-$11.20M–
Q4 FY2024Dec 31, 2024-$15.28M–
Q3 FY2024Sep 30, 2024-$9.37M–
Q2 FY2024Jun 30, 2024-$12.81M–
Q1 FY2024Mar 31, 2024-$9.90M–
Q4 FY2023Dec 31, 2023-$7.13M–
Q3 FY2023Sep 30, 2023-$9.07M–
Q2 FY2023Jun 30, 2023-$811.00K–
Q1 FY2023Mar 31, 2023-$11.41M–

More Mereo BioPharma figures

See a number that looks wrong?